Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
MDA-MB-157 Dinaciclib
0.00031623
pan CDK
Cell cycle
 1.0629 -0.00194
MDA-MB-157 Taxol
0.00031623
Chemo
Chemotherapy
 1.0667 0.01003
MDA-MB-157 Neratinib
0.00031623
EGFR/HER2
RTK
 1.0337 0.00251
HCC1806 Neratinib
0.00031623
EGFR/HER2
RTK
 1.0684 0.00476
PDX1258 Taxol
0.00031623
Chemo
Chemotherapy
 0.9920 0.00522
HCC1428 INK-128
0.00031623
mTORC1/2
PI3K/mTOR
 0.9695 0.00136
MDA-MB-134-VI Neratinib
0.00031623
EGFR/HER2
RTK
 1.3354 0.00352
MDA-MB-157 Palbociclib
0.00031623
CDK4/6
Cell cycle
 0.9482 0.00160
BT-20 Dinaciclib
0.00031623
pan CDK
Cell cycle
 1.0258 -0.00375
BT-20 Torin2
0.00031623
mTOR/ATM/ATR
PI3K/mTOR
 1.0136 0.00054
BT-20 INK-128
0.00031623
mTORC1/2
PI3K/mTOR
 1.0214 -0.00216
MDA-MB-134-VI INK-128
0.00031623
mTORC1/2
PI3K/mTOR
 0.9671 -0.00323
MDA-MB-134-VI Luminespib
0.00031623
HSP90
Misc
 1.3361 -0.01039
MDA-MB-134-VI Trametinib
0.00031623
MEK
MAPK/nRTK
 0.9508 0.00935
MDA-MB-134-VI Torin2
0.00031623
mTOR/ATM/ATR
PI3K/mTOR
 1.0531 0.00467
MDA-MB-157 Volasertib
0.00031623
PLK
Cell cycle
 1.0814 -0.00135
Hs 578T Neratinib
0.00031623
EGFR/HER2
RTK
 1.0519 0.00196
MDA-MB-134-VI Taxol
0.00031623
Chemo
Chemotherapy
 0.5566 0.10198
MDA-MB-134-VI Doxorubicin
0.00031623
Chemo
Chemotherapy
 1.1909 0.00067
MDA-MB-134-VI Volasertib
0.00031623
PLK
Cell cycle
 1.4141 0.00230
MDA-MB-231 Luminespib
0.00031623
HSP90
Misc
 0.9649 0.00301
HCC1806 Taxol
0.00031623
Chemo
Chemotherapy
 1.0636 -0.00191
MDA-MB-134-VI Dinaciclib
0.00031623
pan CDK
Cell cycle
 1.0543 -0.01056
PDX1328 Torin2
0.00031623
mTOR/ATM/ATR
PI3K/mTOR
 0.9759 0.00744
BT-20 Taxol
0.00031623
Chemo
Chemotherapy
 1.0128 0.00568